Last reviewed · How we verify
Placebo Auto-Injector
A placebo auto-injector device delivers no active pharmaceutical ingredient, serving as a control or inert comparator in clinical studies.
A placebo auto-injector device delivers no active pharmaceutical ingredient, serving as a control or inert comparator in clinical studies. Used for Clinical trial control/comparator (not a therapeutic indication).
At a glance
| Generic name | Placebo Auto-Injector |
|---|---|
| Also known as | Placebo |
| Sponsor | Celltrion |
| Modality | Biologic |
| Phase | FDA-approved |
Mechanism of action
Placebo auto-injectors are pharmaceutical delivery devices designed to mimic the appearance, administration route, and user experience of active drug auto-injectors without containing therapeutic agents. They are used in blinded clinical trials to control for injection-related effects, device handling, and psychological factors, allowing researchers to isolate the true pharmacological effects of investigational drugs.
Approved indications
- Clinical trial control/comparator (not a therapeutic indication)
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Nocebo effects (symptom reporting attributable to expectation rather than active drug)
Key clinical trials
- Tirzepatide to Slow Biological Aging (PHASE2)
- GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study) (PHASE3)
- Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity (NA)
- A Phase 3 Study to Evaluate Efficacy & Safety of Subcutaneous CT-P13 in Patients With Moderate to Severe Active Rheumatoid Arthritis (PHASE3)
- A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal) (PHASE3)
- Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia (PHASE3)
- Semaglutide in Auto-HSCT (PHASE2)
- Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Auto-Injector CI brief — competitive landscape report
- Placebo Auto-Injector updates RSS · CI watch RSS
- Celltrion portfolio CI